2018
DOI: 10.18203/2349-3933.ijam20183130
|View full text |Cite
|
Sign up to set email alerts
|

HbA1c as screening biomarker of dyslipidemia in type 2 diabetes mellitus patients

Abstract: Background: Patients with diabetes are considered to be at high risk for dyslipidemia and hypertension and therefore vulnerable to cardiovascular diseases. This study describes the possible role of Glycated Hemoglobin (HbA1c) and serum lipid profile as a biomarker for detecting cardiovascular diseases. The aim of present work is to study the role of HbA1c as a screening biomarker for dyslipidemia in patients with type 2 Diabetes Mellitus (T2DM).Methods: Present study consists of 100 Type 2 DM patients between … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 11 publications
(12 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?